Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FJ9W
|
|||
| Former ID |
DIB016717
|
|||
| Drug Name |
KB-004
|
|||
| Synonyms |
Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [1] | |
| Company |
KaloBios Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ephrin type-A receptor 3 (EPHA3) | Target Info | . | [2] |
| KEGG Pathway | Axon guidance | |||
| Pathway Interaction Database | EphrinA-EPHA pathway | |||
| EPHA forward signaling | ||||
| Reactome | EPH-Ephrin signaling | |||
| EPHA-mediated growth cone collapse | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01211691) Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Kalobios. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.